New hope for Tough-to-Treat myeloma: experimental drug SG2918 enters human trials
Disease control
Not yet recruiting
This early-stage study tests a new drug called SG2918 in 40 people whose multiple myeloma has returned or not responded to prior treatments. The main goal is to check the drug's safety and how well the body tolerates it. Researchers will also measure how the drug moves through th…
Phase: PHASE1, PHASE2 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated May 11, 2026 20:51 UTC